Introduction
Injectable biomaterials are attractive for soft tissue regeneration because they are handled in a minimally invasive manner and can easily adapt to complex defects. However, inadequate vascularization of the injectable constructs has long been a barrier, leading to necrosis or volume reduction after implantation. In this work, we developed a three-step process to synthesize injectable gelatin-derived hydrogels that are capable of controlling growth factor delivery to induce fast angiogenesis.
Methods
In our approach, tyramine was first introduced into gelatin chains to provide enzymatical crosslinking points for gel formation after injection. Next, heparin, a polysaccharide with binding domains to many growth factors, was covalently linked to the tyramine-modified gelatin. Finally, vascular endothelial growth factor (VEGF) was incorporated into the gelatin derivative by binding with the heparin in the gelatin derivative, and an injectable gel with controlled VEGF release was formed by an enzymatic catalytic reaction with hydrogen peroxide (H 2 O 2 ) and horseradish peroxidase (HRP) (Scheme 1).
Scheme 1.
Synthesis of gelatin-based hydrogels
Results and Discussions
In the ATR-FTIR spectra of the synthesized gelatin derivative hydrogel, the appearance of peaks at 1222, 1145 and 1024 cm -1 for the modified gelatin indicates that heparin has been successfully conjugated onto the gelatin (Figure 1) . The gelation time of G/T/H was controlled by varying the concentration of HRP, H 2 O 2 , and the material composition. An in vitro release study indicated that the VEGF loaded in the G/T/H hydrogel was released in a sustained manner for over 3 weeks. A chicken chorioallantoic membrane (CAM) assay and animal experiments were performed to evaluate in vivo bioactivity of the VEGF released from the hydrogels. After 5 days of incubation on CAM, more blood vessels formed surrounding the heparin-modified hydrogels compared to the controls (Figure 2) . The quantitative analysis confirmed that the numbers of blood vessels surrounding the VEGF-containing G/T (30±6) and G/T/H (42±4) gels were significantly higher than the control group (18±3, P<0.05). Additionally, the number of new blood vessels in the G/T/H+VEGF group showed a significant increase compared to the G/T+VEGF group (P<0.05). In vivo implantation experiments shows deeper and denser cell infiltration and angiogenesis in the heparin-modified gelatin/VEGF gels were observed than in the controls after being subcutaneously injected in the dorsal side of mice for 2 weeks (Figure 3) . Bioactivity of the released VEGF from the VEGF-loaded G/T/H hydrogels using a CAM assay Figure 3 . Gross images of the implanted hydrogels 2 weeks after subcutaneous injection.
Conclusions
A gelatin-based injectable hydrogel was synthesized. The gelatin derivative/VEGF is an excellent injectable delivery system for induced angiogenesis of soft tissue regeneration.
